<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03836352</url>
  </required_header>
  <id_info>
    <org_study_id>P1719-SUR-Z11</org_study_id>
    <secondary_id>Keynote 903</secondary_id>
    <nct_id>NCT03836352</nct_id>
  </id_info>
  <brief_title>Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide &amp; Pembrolizumab, in Subjects With Selected Advanced &amp; Recurrent Solid Tumors</brief_title>
  <official_title>A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunoVaccine Technologies, Inc. (IMV Inc.)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ImmunoVaccine Technologies, Inc. (IMV Inc.)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide&#xD;
      with pembrolizumab in subjects with selected advanced and recurrent solid tumours.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase 2 with safety lead-in study to assess the safety and efficacy of&#xD;
      DPX-Survivac, low dose cyclophosphamide, and pembrolizumab combination therapy in subjects&#xD;
      with selected advanced and recurrent solid tumours. Two ovarian cancer arms will be recruited&#xD;
      and randomized in this study, one with and one without cyclophosphamide. All other cohorts&#xD;
      will be single arm, receiving treatment with the triple combination.&#xD;
&#xD;
      Up to 20 subjects, from any cohort, will be enrolled to assess the safety of study treatments&#xD;
      before the study moves to the expansion phase. Once the safety lead-in is completed, the five&#xD;
      cohorts will be expanded to recruit additional subjects following a Simon two stage design.&#xD;
      Enrollment in the ovarian cancer cohort will be randomized 1:1 into two arms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy as measured by objective response rate</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Centrally evaluated using RECIST v1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as measured by the rate of adverse events</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Centrally evaluated using iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Approximately 24 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Cell mediated immunology</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>As measured by antigen specific immune response in peripheral blood</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in immune cell infiltration</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>As measured by multiplex immunohistochemistry</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Bladder Cancer</condition>
  <condition>Microsatellite Instability-High</condition>
  <arm_group>
    <arm_group_label>Arm 1 (All cohorts)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DPX-Survivac, Cyclophosphamide, Pembrolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (Ovarian cohort only)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DPX-Survivac, Pembrolizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DPX-Survivac</intervention_name>
    <description>SubQ injection (q9w)</description>
    <arm_group_label>Arm 1 (All cohorts)</arm_group_label>
    <arm_group_label>Arm 2 (Ovarian cohort only)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>PO (BID)</description>
    <arm_group_label>Arm 1 (All cohorts)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV Infusion (q3w)</description>
    <arm_group_label>Arm 1 (All cohorts)</arm_group_label>
    <arm_group_label>Arm 2 (Ovarian cohort only)</arm_group_label>
    <other_name>MK-3475</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with advanced or metastatic solid tumours who have completed treatment with&#xD;
             first line therapy:&#xD;
&#xD;
               1. Epithelial ovarian, fallopian tube, or peritoneal cancer&#xD;
&#xD;
               2. Hepatocellular carcinoma&#xD;
&#xD;
               3. Non-small cell lung cancer&#xD;
&#xD;
               4. Urothelial cancer&#xD;
&#xD;
               5. Microsatellite instability high solid tumours, other than the above indications&#xD;
&#xD;
          -  Radiologic and/or biochemical evidence of disease progression&#xD;
&#xD;
          -  Completion of pre-treatment tumour biopsy&#xD;
&#xD;
          -  Must have measurable disease by RECIST v1.1&#xD;
&#xD;
          -  Ambulatory with an ECOG 0-1&#xD;
&#xD;
          -  Life expectancy â‰¥ 6 months&#xD;
&#xD;
          -  Meet protocol-specified laboratory requirements&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Chemotherapy or immunotherapy within treatment within 28 days of start of study&#xD;
             treatment&#xD;
&#xD;
          -  Radiotherapy within treatment within 2 weeks of start of study treatment&#xD;
&#xD;
          -  Prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent&#xD;
             directed to another stimulatory or co-inhibitory T cell receptor where subject was&#xD;
             discontinued from that treatment due to a Grade 3 or higher immune-related toxicity&#xD;
&#xD;
          -  For NSCLC subjects: Known EGFR mutations or ALK rearrangements&#xD;
&#xD;
          -  Prior receipt of survivin-based vaccine(s) and/or immunotherapies&#xD;
&#xD;
          -  Concurrent second malignancy other than non-melanoma skin cancer, cervical carcinoma&#xD;
             in situ, or controlled bladder cancer&#xD;
&#xD;
          -  Clinical ascites or pleural fluid that cannot be managed&#xD;
&#xD;
          -  Malignant bowel obstruction or recent history of bowel obstruction&#xD;
&#xD;
          -  For OvCa, subjects with any single lesion greater than 5 cm&#xD;
&#xD;
          -  Autoimmune disease requiring treatment within the last two years (except replacement&#xD;
             therapy)&#xD;
&#xD;
          -  Recent history of thyroiditis&#xD;
&#xD;
          -  Any history of (non-infectious) pneumonitis that required steroid therapy or current&#xD;
             pneumonitis&#xD;
&#xD;
          -  Presence of a serious acute or chronic infection&#xD;
&#xD;
          -  Active CNS metastases and/or carcinomatous meningitis&#xD;
&#xD;
          -  GI condition that might limit absorption of oral agents&#xD;
&#xD;
          -  Allogenic tissue/solid organ transplant&#xD;
&#xD;
          -  Other serious intercurrent chronic or acute illness, including myocardial infarction&#xD;
             or cerebrovascular event within 6 months&#xD;
&#xD;
          -  Ongoing treatment with steroid therapy or other immunosuppressive&#xD;
&#xD;
          -  Receipt of live attenuated vaccines&#xD;
&#xD;
          -  Acute or chronic skin and/or microvascular disorders&#xD;
&#xD;
          -  Edema or lymphedema in the lower limbs &gt; grade 2&#xD;
&#xD;
          -  Severe hypersensitivity (â‰¥ Grade 3) to pembrolizumab&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>58724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Wolf</last_name>
      <phone>520-694-9090</phone>
      <email>amw8@arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Rachna Shroff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center: Samuel Oschin Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kari Kayser</last_name>
      <phone>310-967-0694</phone>
      <email>kari.kayser@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Alain Mita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boca Raton Regional Hospital, Lynn Cancer Institute</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Godbout</last_name>
      <phone>561-955-4800</phone>
      <phone_ext>1014</phone_ext>
      <email>SGodbout@brrh.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Grabelsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of the Treasure Coast</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Hematology and Oncology</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Archana Pathak</last_name>
      <phone>727-344-6569</phone>
      <phone_ext>1025</phone_ext>
      <email>apathak@comphemonc.com</email>
    </contact>
    <contact_backup>
      <last_name>Deborah Kisko</last_name>
      <phone>727-942-7070</phone>
      <phone_ext>8002</phone_ext>
      <email>dkisko@comphemonc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Pratibha Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute: The Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lydia G Cox</last_name>
      <phone>404-778-5569</phone>
      <email>lydia.g.cox@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Manali Bhave, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James Brown Graham Cancer Center:University of Louisville Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Schoenbachler</last_name>
      <phone>502-562-4673</phone>
      <email>Jennifer.Schoenbachler@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Rebecca Redman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Cancer Institute</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Scuderi</last_name>
      <phone>504-842-7693</phone>
      <email>heather.scuderi@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Marc Matrana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allina Health, Virginia Piper Cancer Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Hite, RN, MSN</last_name>
      <phone>612-863-5501</phone>
      <email>jennifer.hite@allina.com</email>
    </contact>
    <investigator>
      <last_name>Christian Squillante, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christus St. Vincent Regional Cancer Center</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Rodriguez</last_name>
      <phone>505-913-8935</phone>
      <email>andrea.rodriguez@stvin.org</email>
    </contact>
    <investigator>
      <last_name>Olivier Rixe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Sklow</last_name>
      <phone>718-405-8535</phone>
      <email>charlotte.sklow@einsteinmed.org</email>
    </contact>
    <investigator>
      <last_name>Andreas Kaubisch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Winthrop Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Himmel</last_name>
      <phone>516-663-1216</phone>
      <email>Jennifer.Himmel@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Eva Chalas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Toledo</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Smiddy</last_name>
      <phone>419-383-6962</phone>
      <email>stephanie.smiddy@utoledo.edu</email>
    </contact>
    <investigator>
      <last_name>Roland Skeel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>William Osler Health System</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6R3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Henry Conter, MD</last_name>
      <phone>905-494-2120</phone>
      <phone_ext>57264</phone_ext>
      <email>Henry.Conter@williamoslerhs.ca</email>
    </contact>
    <investigator>
      <last_name>Henry Conter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Center</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Center</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liselle Chieverton</last_name>
      <phone>905-895-4521</phone>
      <phone_ext>2297</phone_ext>
      <email>lchieverton@southlakeregional.org</email>
    </contact>
    <investigator>
      <last_name>Shaqil Kassam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna O'Brien</last_name>
      <phone>613-737-7700</phone>
      <phone_ext>70306</phone_ext>
      <email>aobrien@ohri.ca</email>
    </contact>
    <investigator>
      <last_name>Rakesh Goel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Research Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilda Carvalhana</last_name>
      <phone>(416) 480-5000</phone>
      <phone_ext>87435</phone_ext>
      <email>Ilda.Carvalhana@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Helen MacKay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Levac</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>13727</phone_ext>
      <email>xavier.levac.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Diane Provencher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de QuÃ©bec-UniversitÃ© Laval</name>
      <address>
        <city>QuÃ©bec</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maryse Gingras</last_name>
      <phone>418-691-5781</phone>
      <email>maryse.gingras@chudequebec.ca</email>
    </contact>
    <investigator>
      <last_name>Vincent Castonguay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 7, 2019</study_first_submitted>
  <study_first_submitted_qc>February 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2019</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T cell activation</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Ovarian</keyword>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Non-small Cell Lung</keyword>
  <keyword>Bladder</keyword>
  <keyword>Microsatellite Instability-High</keyword>
  <keyword>Survivin</keyword>
  <keyword>Anti-PD-1</keyword>
  <keyword>MK-3475</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Microsatellite Instability</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

